Open AccessActivity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)
Author(s) -
Cecília G Carvalhaes,
Hélio S. Sader,
Jennifer M Streit,
Mariana Castanheira,
Rodrigo E. Mendes
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01667-21
Subject(s) - daptomycin , linezolid , enterococcus , enterococcus faecium , staphylococcus aureus , microbiology and biotechnology , methicillin resistant staphylococcus aureus , vancomycin , vancomycin resistant enterococcus , antibiotics , drug resistance , medicine , biology , bacteria , genetics
Oritavancin displayed potent and stable activity (MIC90 range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistantStaphylococcus aureus (MRSA) and resistant subsets ofEnterococcus spp. Daptomycin and linezolid were also active against methicillin-resistantS. aureus and vancomycin-resistantEnterococcus (VRE). Only oritavancin and linezolid remained active againstEnterococcus faecium isolates displaying an elevated daptomycin MIC (i.e., 2 to 4 mg/L).